¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"inhibition ratio"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • antidromic inhibition
    ¿ª¹æÇâ¾ïÁ¦
  • afferent inhibition
    µé½Å°æ¾ïÁ¦, ±¸½É¾ïÁ¦
  • agar gel precipitin inhibition test
    ¿ì¹«°Öħ°­¼Ò¾ïÁ¦°Ë»ç
  • allogenic inhibition
    µ¿Á¾ÀÌÇü¾ïÁ¦
  • competitive inhibition
    °æÀï¾ïÁ¦
  • complement fixation inhibition test
    º¸Ã¼°áÇÕ¾ïÁ¦°Ë»ç
  • contact inhibition
    Á¢Ã˾ïÁ¦
  • density dependent inhibition
    ¹ÐµµÀÇÁ¸¾ïÁ¦
  • enzyme inhibition
    È¿¼Ò¾ïÁ¦
  • feedback inhibition
    µÇ¸ÔÀÓ¾ïÁ¦
  • hemagglutination inhibition antibody
    ÀûÇ÷±¸ÀÀÁý¾ïÁ¦Ç×ü
  • hemagglutination inhibition test
    Ç÷±¸ÀÀÁý¾ïÁ¦°Ë»ç
  • hemagglutination-inhibition reaction
    ÀûÇ÷±¸ÀÀÁý¾ïÁ¦¹ÝÀÀ
  • irreversible inhibition
    ºñ°¡¿ª¾ïÁ¦
  • immunologic inhibition
    ¸é¿ª¾ïÁ¦
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 14 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • inhibition
    ¾ïÁ¦, ÀúÁö
  • competitive inhibition
    °æÀï¾ïÁ¦
  • reciprocal inhibition
    »ó¹Ý¾ïÁ¦, »óÈ£¾ïÁ¦
  • inhibition reaction
    ¾ïÁ¦¹ÝÀÀ
  • inhibition test
    ¾ïÁ¦°Ë»ç
  • ratio
    ºñ, À²
  • correlation ratio
    »ó°üºñ
  • inspiratory expiratory ratio
    µé¼û³¯¼ûºñÀ², ÈíÈ£±â´ëºñ
  • odds ratio
    ±³Â÷ºñ
  • scatter-maximum ratio
    ÃÖ´ë»ê¶õºñ
  • segregation ratio
    ºÐ¸®ºñ
  • sex ratio
    ¼ººñ
  • signal-to-noise ratio
    ½ÅÈ£´ëÀâÀ½ºñ
  • uptake ratio
    ¼·ÃëÀ²
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • afferent inhibition
    µé½Å°æ¾ïÁ¦, ±¸½É¾ïÁ¦
  • agar gel precipitin inhibition test
    ¿ì¹«°Öħ°­¼Ò¾ïÁ¦°Ë»ç
  • allogenic inhibition
    µ¿Á¾ÀÌÇü¾ïÁ¦
  • antidromic inhibition
    (¢¡recurrent inhibition) ȸ±Í¾ïÁ¦
  • hemagglutination inhibition antibody
    ÀûÇ÷±¸ÀÀÁý¾ïÁ¦Ç×ü
  • colony inhibition test
    ¼¼Æ÷±ºÇü¼º¾ïÁ¦°Ë»ç, Áý¶ôÇü¼º¾ïÁ¦°Ë»ç
  • competitive inhibition
    °æÀï¾ïÁ¦, °æÇÕ¾ïÁ¦
  • complement fixation inhibition test
    º¸Ã¼°áÇÕ¾ïÁ¦½ÃÇè
  • contact inhibition
    Á¢Ã˾ïÁ¦
  • density dependent inhibition
    ¹ÐµµÀÇÁ¸¾ïÁ¦
  • enzyme inhibition
    È¿¼Ò¾ïÁ¦
  • feedback inhibition
    µÇ¸ÔÀÓ¾ïÁ¦
  • fertility inhibition
    ¼öÅÂÀÎÀÚÀü´ÞÀúÁö
  • migration inhibition factor
    Æ÷½Ä¼¼Æ÷À̵¿ÀúÇØÀÎÀÚ
  • hemagglutination inhibition test
    Ç÷±¸ÀÀÁý¾ïÁ¦°Ë»ç
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • AC/A ratio->ratio of accommodative convergence to accommodation
    Á¶ÀýÆøÁÖºñ
  • A£¯G ratio=£¾albumin globulin ratio
    A£¯G ºñ.
  • U/S osmol ratio => urine/serum osmol ratio
    ¼Òº¯/Ç÷û ¿À½º¸ôºñ
  • DeRitis ratio
    µå¸®Æ¼½ººñÀ²
  • Donnan ratio
    µ·³­À²
  • G/N ratio
    G/Nºñ Æ÷µµ´ç°ú Áú¼ÒÀÇ ºñÀ² .
  • INR => International Normalized Ratio
    ±¹Á¦Á¤»óÈ­ºñÀ²
  • International Normalized Ratio
    ±¹Á¦Á¤»óÈ­ºñÀ²
  • International Normalized Ratio=INR
    ±¹Á¦Á¤»óÈ­ºñ
  • L/S ratio
    L/S ºñÀ²
  • OER [=oxygen enhancement ratio]
    »ê¼Ò°­È­À²
  • S-D ratio
    ¼öÃà±â-À̿ϱ⠺ñ (â¥õêÑ¢-ì¬èÐÑ¢ Ýï)
  • SNR (signal to noise ratio)
    ½ÅÈ£´ë ÀâÀ½ºñÀ²
  • V/Q => ventilation/perfusion ratio
    ȯ±â/°ü·ùºñ
  • VA/Q => ventilation/perfusion ratio
    ȯ±â/°ü·ù ºñ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • dextrosenitrogen ratio =DN ratio
    Æ÷µµ´çÁú¼Òºñ.
  • afferent inhibition
    ±¸½É¼º ¾ïÁ¦(Ï´ãýàõåäð¤)
  • agar gel precipitin inhibition test
    ÇÑõ°Öħ°­¼Ò ÀúÁö½ÃÇè(¡­ ˽áÈðæò­ãËúÐ).
  • agglutination inhibition test
    ÀÀÁý¾ïÁ¦½ÃÇè(¡­åäð¤ãËúÐ).
  • allogen(a)ic inhibition
    µ¿Á¾¼¼Æ÷ÀúÁö(¡­á¬øàðæò­).
  • antidromic inhibition
    ¿ª¹æÇ⼺ ¾ïÁ¦ (¡­åäð¤)
  • cardiac inhibition
    ½ÉÀå ¾ïÁ¦(ãýíôåäð¤)
  • cell,contact inhibition
    Á¢Ã˾ïÁ¦ (ïÈõºåäð¤)
  • chemical inhibition isoagglutinin
    È­ÇÐÀû ¾ïÁ¦ µ¿Á¾ÀÀÁý¼Ò
  • colony inhibition
    ±ÕÁý¶ô¾ïÁ¦(жó¢Õªåäð¤), ±ºÃ¼¾ïÁ¦(ÏØô÷åäð¤).
  • colony inhibition test
    Áý¶ôÇü¼º ÀúÁö½ÃÇè, ¼¼Æ÷±ºÇü¼º ÀúÁö½ÃÇè
  • competitive antagonism/inhibition
    °æÀïÀû ±æÇ×/¾ïÁ¦.
  • competitive inhibition
    °æÀïÀû ¾ïÁ¦, °æÇÕ¼º ¾ïÁ¦(Ìæùêàõåäð¤).
  • competitive inhibition
    °æÇÕÀúÇØ(ÌæùêîÁúª).
  • competitive inhibition
    °æÀïÀû¾ïÁ¦
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • inhibition ratio
    ÀúÇØÀ²(îÁúªëÒ)
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • absorption ratio
    Èí¼öÀ² (ýåâ¥ëÒ)
  • acceptor-control ratio
    ¼ö¿ëü Á¦¾îÀ² (â¥é»ô÷ ð¤åÙëÒ)
  • affinity ratio
    ģȭºñ(öÑûúÝï)
  • A/G ratio
    A/G ºñ (Ýï)
  • albumin/globulin ratio
    ¾ËºÎ¹Î/±Û·ÎºÒ¸° ºñ(Ýï)
  • asymmetry ratio
    ºÒ±Õµîºñ (ÝÕгÔõÝï)
  • A+T/G+C ratio
    A+T/G+C ºñ (Ýï)
  • base-pair ratio
    ¿°±â¦ ºñ(Ýï)
  • base ratio
    ¿°±âºñ(ç¤ÐñÝï)
  • channels ratio method
    ä³Î ºñÀ²¹ý(Ýï×ËÛö)
  • coding ratio
    ºÎÈ£ºñ(ݬûÜÝï)
  • dichroic ratio
    ÀÌ»öºñ(ì£ßäÝï)
  • disequilibrium ratio
    ºÒÆòÇü ºñÀ²(ÝÕøÁû¬Ýï×Ë)
  • dissymmetry ratio
    ºÒ¿ÏÀü´ëĪ ºñÀ²(ÝÕèÇîïÓßöàÝï×Ë)
  • distribution ratio
    "ºÐÆ÷À²(ÝÂøÖëÒ), (ÔÒ) partition coefficient"
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 14 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • hemagglutination inhibition test
    Ç÷±¸ÀÀÁý¾ïÁ¦½ÃÇè
  • inhibition
    ¾ïÁ¦, ÀúÁö, ÀúÇØ
  • cardiothoracic ratio
    ½ÉÈä(°û)ºñ, ½ÉÈä°è¼ö
  • contrast enhancement ratio
    Á¶¿µÁõ°­ºñ
  • contrast to noise ratio
    ´ëÁ¶ÀâÀ½ºñ
  • depth to width ratio
    ±íÀÌÆøºñÀ²
  • gyromagnetic ratio
    ȸÀüÀÚ±âºñÀ²
  • heart lung ratio
    ½ÉÆó°è¼ö
  • magnetization transfer ratio [=MTR]
    ÀÚÈ­Àü´ÞºñÀ²
  • ratio
    ºñ
  • signal to noise ratio [=SNR]
    ½ÅÈ£´ëÀâÀ½ºñ
  • SNR [=signal to noise ratio]
    ½ÅÈ£´ëÀâÀ½ºñÀ²
  • uptake ratio
    ¼·ÃëÀ²
  • velocity ratio
    ¼Óµµºñ
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
RI radiation intensity; radioactive isotope; radioimmunology; recession index; recombinant inbred [stra...
EIC elastase inhibition capacity; enzyme inhibition complex
LAI latex particle agglutination inhibition; leukocyte adherence inhibition
AR absolute risk; accounts receivable; achievement ratio; actinic reticuloid [syndrome]; active resista...
L/S lactase/sucrase [ratio]; lecithin/ sphingomyelin [ratio]; lipid/saccharide [ratio]; longitudinal sec...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
L/S ratio Lecithin/sphingomyelin ratio
ACEi Angiotensin I converting enzyme inhibition
BIS Behavioral Inhibition System
CEI Converting enzyme inhibition
DSI Depolarisation-induced suppression of inhibition
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • allogeneic inhibition
    µ¿Á¾ ÀÌÇü ¾ïÁ¦
  • antagonistic inhibition
    ±æÇ×±Ù ¾ïÁ¦, ±æÇ×Àû ¾ïÁ¦, ±æÇ×Àû ÀúÇØ
  • antidromic inhibition
    ¿ª¹æÇ⼺ ¾ïÁ¦
  • competitive inhibition
    °æÀïÀû ¾ïÁ¦, °æÇÕ¼º ¾ïÁ¦
    ¾î¶² ¼ö¿ëü¿¡ ´ëÇØ °áÇÕ·ÂÀÌ Å« ¹°ÁúÀÌ »ó´ëÀûÀ¸·Î °áÇÕ·ÂÀÌ ¾àÇÑ ´Ù¸¥ ¹°ÁúÀÇ °áÇÕÀ» ¾ïÁ¦ÇÏ´Â °Í.
  • complement fixation inhibition test
    º¸Ã¼ °íÁ¤ ÀúÇØ ½ÃÇè
  • cyto- ¼¼Æ÷¿ÍÀÇ °ü°è¸¦ ³ªÅ¸³»´Â Á¢µÎ¾î.

    cyto-inhibition

    ¼¼Æ÷ ¾ïÁ¦ ÀÛ¿ë
    ޽ÄÇÑ ¼¼±Õ ¶Ç´Â ¹ÙÀÌ·¯½º¸¦ ¿ëÇØÇϰųª È­Çпä¹ýÁ¦¿¡ ÀÇÇÑ È­ÇÐÀû ÆÄ±«·ÎºÎÅÍ ¹æ¾îÇÏ´Â ½Ä ¼¼Æ÷ÀÇ ÀÛ¿ë.
  • enzyme inhibition
    È¿¼Ò ¾ïÁ¦
  • factor macrophage migration inhibition
    ´ë½Ä ¼¼Æ÷ À¯ÁÖ ÀúÁö ÀÎÀÚ
  • hapten inhibition test
    ÇÕÅÙ ÀúÇØ ½ÃÇè
    Ç×üÀÇ Ç׿ø Ư¼ö °áÇÕ ºÎÀ§¸¦ µ¤´Â ÇÕÅÙÀ» ÀÌ¿ëÇÏ¿© Ç׿ø °áÁ¤±âÀÇ Ç÷ûÇÐÀû Ư¼ºÀ» °Ë»çÇÏ´Â ½ÃÇè.
  • hemagglutination inhibition test
    ÀûÇ÷±¸ ÀÀÁý ¾ïÁ¦ ½ÃÇè
  • inhibition
    ¾ïÁ¦, ÀúÁö, ÀúÇØ
    °úÁ¤ÀÇ ¾ï¾Ð
  • inhibition reaction
    ¾ïÁ¦, ¾ïÁ¦ ¹ÝÀÀ, ÀúÁö, ÀúÁö ¹ÝÀÀ
  • inhibition zone
    ¾ïÁ¦´ë
    ħ°­ ¶Ç´Â ÀÀÁý ¹ÝÀÀ¿¡¼­ Ç×ü ³óµµ°¡ ³ôÀº Ç÷û¿¡¼­´Â Ç׿ø ÀÔÀÚ¿Í ¹ÝÀÀÀ» ³ªÅ¸³»Áö ¾Ê´Â Çö»ó.
  • lateral inhibition
    Ãø¹æ ¾ïÁ¦
    ÈïºÐÇϰí ÀÖ´Â ¿ä¼Ò¿¡ ÀÇÇÏ¿© ÀÎÁ¢ÇÏ´Â ¿ä¼ÒÀÇ È°µ¿ÀÌ ¾ïÁ¦µÇ´Â Çö»ó.
  • lingering inhibition

    lingissimus capitis (µÎÃÖÀå±Ù

    »óÃø 4¡­5 ÈäÃßÀÇ È¾µ¹±â¿Í ÇÏÃø 3¡­4 °æÃßÀÇ °üÀýµ¹±â¿¡¼­ ±â½ÃÇÏ¿© ÃøµÎ°ñÀÇ À¯¾çµ¹±â¿¡¼­ Á¤ÁöÇÑ´Ù. °æ ½Å°æ °¡ÁöÀÇ Áö¹è¸¦ ¹ÞÀ¸¸ç, ¸Ó¸®¸¦ ÈĹæÀ¸·Î ´ç±â°í ȸÀü½ÃŲ´Ù.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
allogeneic inhibition Inhibition or injury to allogeneic cells that occurs when lymphocytes are mixed and cultured with other cells of different genotypes in vitro.
(05 Mar 2000)
macrophage inhibition factor <cytokine> A group of lymphokines (including a 14 kD glycoprotein) produced by activated T lymphocytes that reduces macrophage mobility and probably increases macrophage macrophage adhesion.
(18 Nov 1997)
macrophage migration inhibition test A test which measures the presence of migration-inhibitory factor. Usually peritoneal macrophages are placed in a capillary tube in the presence or absence of supernatants from activated T-cells. If MIF is present, the migration of monocyte/macrophages is reduced.
Synonym: macrophage migration inhibition test, migration inhibition test.
(05 Mar 2000)
reactive inhibition Tendency toward a lessened strength of response due to practice or activity. It is independent of the effect of reward and is a direct function of time interval since the last response and the number of preceding responses.
(12 Dec 1998)
reciprocal inhibition Contraction in a muscle is accompanied by a loss of tone or by relaxation in the antagonistic muscle.
Synonym: reciprocal inhibition.
(05 Mar 2000)
reflex inhibition A situation in which sensory stimuli decrease reflex activity.
(05 Mar 2000)
cell migration inhibition Phenomenon of cell-mediated immunity measured by in vitro inhibition of the migration or phagocytosis of antigen-stimulated leukocytes or macrophages. Specific assays have been developed to estimate levels of migration-inhibitory factor, immune reactivity against tumour-associated antigens, and immunosuppressive effects of infectious microorganisms.
(12 Dec 1998)
central inhibition <physiology> Suppression or diminution of outgoing impulses from a reflex centre.
(05 Mar 2000)
residual inhibition The inhibition or suppression of tinnitus by use of a sound-generating device (residual inhibitor) which masks the sounds of tinnitus and produces a residual sound-inhibiting effect when the device is turned off.
(05 Mar 2000)
retroactive inhibition The partial or complete obliteration of memory by a more recent event, particularly new learning.
Compare: proactive inhibition.
(05 Mar 2000)
migration inhibition test A test which measures the presence of migration-inhibitory factor. Usually peritoneal macrophages are placed in a capillary tube in the presence or absence of supernatants from activated T-cells. If MIF is present, the migration of monocyte/macrophages is reduced.
Synonym: macrophage migration inhibition test, migration inhibition test.
(05 Mar 2000)
Wedensky inhibition Inhibition of muscle response resulting from application of a series of rapidly repeated stimuli to the motor nerve where slower frequency of stimulation results in muscle response.
(05 Mar 2000)
competitive inhibition <chemistry> Inhibitor that occupies the active site of an enzyme or the binding site of a receptor and prevents the normal substrate or ligand from binding.
at sufficiently high concentration of the normal ligand inhibition is lost: the Km is altered by the competitive inhibitor, but the Vmax remains the same.
(05 Jan 1998)
contact inhibition The inhibition of continued growth and division of a cell or colony due to physical contact with other cells or colonies. The stopping of continued growth when a certain density of cells has been reached.
The momentary stopping of all movement when a mobile cell runs into another cell.
(09 Oct 1997)
contact inhibition of growth See: density dependent inhibition.
(18 Nov 1997)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • inhibition
    ¾ïÁ¦
  • feedback inhibition
    Çǵå¹é ÀúÇØ
  • inhibition
    ±ÝÁö;±ÝÁ¦;¾ïÁ¦;¾ï¾Ð;(¿µ±¹±³)¼º¹«ÁýÇà±ÝÁö¸í·É;(¿µ¹ý)¼Ò¼ÛÁøÇàÁ¤Áö¿µÀå
  • ratio
    ºñ
  • cash ratio
    (ÀºÇàÀÇ ÁöºÒ Áغñ±ÝÀÇ ÃÑ¿¹±Ý¿¡ ´ëÇÑ)Çö±Ý ºñÀ²
  • compression ratio
    (¿£ÁøÀÇ) ¾ÐÃàºñ
  • conversion ratio
    Àüȯ ºñÀ²(Çٺп­½Ã ÇϳªÀÇ ¿øÀÚ¿¡¼­ »ý±â´Â ¿øÀÚÀÇ ¼ö
  • cost performance (ratio)
    ºñ¿ë´ë ¼º´Éºñ
  • direct ratio
    (¼ö)Á¤ºñ;Á¤ºñ·Ê
  • elderly dependency ratio
    ³ë·ÉÀÚ(ÇÇ)ºÎ¾ç·ü
  • focal ratio
    =F-NUMBER
  • inverse ratio
    (¼ö)¹Ýºñ;¿ªºñ
  • mass ratio
    Áú·®ºñ (ÃßÁøºÎ¸¦ Á¦¿ÜÇÑ ·ÎÄÏ º»Ã¼¿¡ ´ëÇÑ ÃÑÁß·®ÀÇ ºñÀ²,ÃßÁø¾à ÃæÀüÀ²)
  • payout ratio
    ¹è´ç ¼ºÇâ
  • priceearnings ratio
    ÁÖ°¡ ¼öÀÍ·ü 9
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á